What is the Zometa 1–2 mg Infusion?

Zometa is a bisphosphonate medication containing the active ingredient zoledronic acid. It is typically used at higher doses to strengthen bones and prevent complications associated with bone diseases and bone metastases. It works by inhibiting the activity of osteoclasts—the cells responsible for bone breakdown—thereby reducing bone resorption and increasing bone density.

What are the benefits of the Zometa 1–2 mg Infusion?

Studies have shown that infusions of 1–2 mg of zoledronic acid can activate the body’s own gamma delta T cells. These gamma delta T cells play a crucial role in the immune system’s defense against tumors and are often reduced in cancer patients. This subtype of T cells is capable of efficiently mediating the destruction of cancer cells, and they are especially effective at targeting and killing cancer stem cells. When used in combination with dendritic cell therapy, Zometa infusions can help activate these T cells within the body.

How is the Zometa 1–2 mg Infusion administered?

The Zometa 1–2 mg infusion is administered intravenously (IV) under medical supervision.

• Administration: The infusion is delivered through a vein, typically over a period of 15–30 minutes, depending on the patient’s condition.
• Post-infusion Monitoring: The patient is monitored for a short time afterward to detect any potential side effects early.